Citigroup Inc Macrogenics Inc Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Macrogenics Inc stock. As of the latest transaction made, Citigroup Inc holds 45,643 shares of MGNX stock, worth $148,796. This represents 0.0% of its overall portfolio holdings.

Number of Shares

45,643

Previous 24,635 85.28%

Holding current value

$148,796

Previous $104,000 44.23%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$3.0 - $5.55 $63,024 - $116,594	21,008 Added 85.28%	45,643 $150,000
Q2 2024 Aug 12, 2024	SELL	$3.31 - $18.51 $928,259 - $5.19 Million	-280,441 Reduced 91.92%	24,635 $104,000
Q1 2024 May 10, 2024	BUY	$9.77 - $21.47 $2.53 Million - $5.55 Million	258,605 Added 556.49%	305,076 $4.49 Million
Q4 2023 Feb 09, 2024	BUY	$4.48 - $10.11 $198,401 - $447,731	44,286 Added 2026.82%	46,471 $447,000
Q3 2023 Nov 09, 2023	SELL	$4.48 - $6.19 $82,087 - $113,419	-18,323 Reduced 89.35%	2,185 $10,000
Q2 2023 Aug 10, 2023	BUY	$4.62 - $7.54 $85,761 - $139,965	18,563 Added 954.4%	20,508 $109,000
Q1 2023 May 11, 2023	SELL	$4.82 - $7.24 $2,448 - $3,677	-508 Reduced 20.71%	1,945 $13,000
Q4 2022 Feb 09, 2023	SELL	$3.34 - $6.98 $4,802 - $10,037	-1,438 Reduced 36.96%	2,453 $16,000
Q3 2022 Nov 10, 2022	SELL	$3.01 - $5.22 $7,257 - $12,585	-2,411 Reduced 38.26%	3,891 $13,000
Q2 2022 Aug 10, 2022	SELL	$2.25 - $9.99 $67,014 - $297,542	-29,784 Reduced 82.54%	6,302 $19,000
Q1 2022 May 12, 2022	SELL	$8.12 - $16.9 $882,351 - $1.84 Million	-108,664 Reduced 75.07%	36,086 $318,000
Q4 2021 Feb 10, 2022	BUY	$15.91 - $21.88 $57,721 - $79,380	3,628 Added 2.57%	144,750 $2.32 Million
Q3 2021 Nov 10, 2021	BUY	$19.74 - $28.7 $2.79 Million - $4.05 Million	141,122 New	141,122 $2.96 Million

Others Institutions Holding MGNX

# of Institutions

132

Shares Held

55.4M

Call Options Held

215K

Put Options Held

238K

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account